Research and Markets: Global Market: Biopharmaceuticals Market Trends & Competition

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/bfdd7f/global_market_bio) has announced the addition of the "Global Market: Biopharmaceuticals Market Trends & Competition" report to their offering.

Todays pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals. And today, biopharmaceuticals account for 25% of all pharmaceuticals in the development pipeline. The publisher expects that biopharmaceuticals will maintain double digit growth in the years to come, and form a rapidly growing market.

Eyeing this dramatically expanding market, companies are expanding biopharmaceutical discovery and development, and becoming active in M&A activities including involvement in bio-ventures. As a result, competition is becoming increasingly fierce.

Disease Categories: Alzheimers disease, Anemia, Arthritis, Asthma, Cancer, CAPS, Diabetes, Fabry disease, Gauchers disease, Growth hormone deficiency, Hepatitis C, HIV, Lupus, Multiple sclerosis, Neutropenia, Osteoporosis, Parkinsons disease, Transplant rejection, Ulcerative colitis, Vaccines, Other conditions.

Key Topics Covered:

1. Market Overview

2. Worldwide Biopharmaceutical Drug Market Trends, 2009 2013

3. US Biopharmaceutical Drug Market, 2009 - 2013

4. Worldwide Innovative Biopharmaceutical Drug Development by Disease Categories

5. Worldwide Biopharmaceutical Strategy by Major Company

6. Important Findings and Suggestions/Recommendations for Business Opportunities

7. Appendix

Companies Mentioned:

  • Abbott Laboratories
  • AMBiS
  • Amgen
  • Bayer
  • Biogen Idec
  • Bristol-Myers Squibb
  • Chugai Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Elan
  • Eli Lilly
  • Genetech
  • Genzyme
  • GlaxoSmithKline
  • Hayashi Kasei Co. Ltd.
  • Human Genome Sciences
  • Johnson & Johnson
  • Katakura Industries Co. Ltd.
  • Kyowa Hakko Kirin Co. Ltd.
  • Merck
  • Merck Serono
  • + many more

For more information visit http://www.researchandmarkets.com/research/bfdd7f/global_market_bio



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.